Cannabis GMP

cannabisgmp.co.il

Cannabis GMP Ltd. provides consultancy for companies engaged with developing and manufacturing of Cannabis/Marijuana products, medication and medical devices combined with Cannabis. Cannabis GMP is a subsidiary of Bio-Chem Ltd. (2007) specializing in consulting companies from the Pharmaceutical, Medical Devices, and supplements fields. Cannabis GMP is focused on value creation and project outcomes, allowing our customers to develop and manufacture high-quality Cannabis products with the emphasis on effectiveness, improving productivity, quality control and business results.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

PUMA BIOTECHNOLOGY ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ALISERTIB

Puma Biotechnology | September 21, 2022

news image

Puma Biotechnology, Inc. a biopharmaceutical company, announced an agreement with Takeda to license the worldwide research and development and commercial rights to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A. Alisertib is an adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Alisertib h...

Read More

Medical, Industry Outlook

GENEDX ANNOUNCES NEW TOOL TO HELP HARNESS HUMAN PANGENOME DIVERSITY FOR CLINICAL INTERPRETATION OF VARIANTS

Globenewswire | June 27, 2023

news image

GeneDx a leader in delivering improved health outcomes through genomic and clinical insights, today published a paper in Nature Methods, titled “Multiscale analysis of pangenomes enables improved representation of genomic diversity for repetitive and clinically relevant genes,” in which researchers developed a new computational tool, the PanGenome Research-Tool Kit (PGR-TK), for scalable analysis of clinically relevant genes that were previously too complex to analyze. ...

Read More

FIRMENICH OPENS NEW BIOTECHNOLOGY AND NATURALS PILOT PLANT AND LABORATORY IN GENEVA

Firmenich | October 01, 2020

news image

Firmenich, the world's largest privately-owned Perfume and Taste company, is proud to announce the opening of its new biotechnology and naturals pilot plant and laboratory in Geneva. Benefiting from the latest digital technology, the facility opens a new era for the development of ingredients and clean label solutions by providing faster speed-to-market and greater flexibility for customer collaboration. Integrated into the Group's flagship ingredients production site at La Plaine, Genev...

Read More

Industrial Impact

GUARDANT HEALTH RECEIVES REGULATORY APPROVAL FROM SINGAPORE'S HEALTH SCIENCES AUTHORITY FOR GUARDANT360® CDX BLOOD TEST FOR PATIENTS

PRNewswire | May 30, 2023

news image

Guardant Health, Inc. announced that Singapore's Health Sciences Authority has granted regulatory approval of Guardant360® CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling in patients with advanced solid cancers. The Guardant360 CDx test was also approved as a companion diagnostic to identify patients with advanced non-small cell lung cancer with epidermal growth factor receptor alterations who may benefit from treatment with TAG...

Read More
news image

Cell and Gene Therapy

PUMA BIOTECHNOLOGY ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ALISERTIB

Puma Biotechnology | September 21, 2022

Puma Biotechnology, Inc. a biopharmaceutical company, announced an agreement with Takeda to license the worldwide research and development and commercial rights to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A. Alisertib is an adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Alisertib h...

Read More
news image

Medical, Industry Outlook

GENEDX ANNOUNCES NEW TOOL TO HELP HARNESS HUMAN PANGENOME DIVERSITY FOR CLINICAL INTERPRETATION OF VARIANTS

Globenewswire | June 27, 2023

GeneDx a leader in delivering improved health outcomes through genomic and clinical insights, today published a paper in Nature Methods, titled “Multiscale analysis of pangenomes enables improved representation of genomic diversity for repetitive and clinically relevant genes,” in which researchers developed a new computational tool, the PanGenome Research-Tool Kit (PGR-TK), for scalable analysis of clinically relevant genes that were previously too complex to analyze. ...

Read More
news image

FIRMENICH OPENS NEW BIOTECHNOLOGY AND NATURALS PILOT PLANT AND LABORATORY IN GENEVA

Firmenich | October 01, 2020

Firmenich, the world's largest privately-owned Perfume and Taste company, is proud to announce the opening of its new biotechnology and naturals pilot plant and laboratory in Geneva. Benefiting from the latest digital technology, the facility opens a new era for the development of ingredients and clean label solutions by providing faster speed-to-market and greater flexibility for customer collaboration. Integrated into the Group's flagship ingredients production site at La Plaine, Genev...

Read More
news image

Industrial Impact

GUARDANT HEALTH RECEIVES REGULATORY APPROVAL FROM SINGAPORE'S HEALTH SCIENCES AUTHORITY FOR GUARDANT360® CDX BLOOD TEST FOR PATIENTS

PRNewswire | May 30, 2023

Guardant Health, Inc. announced that Singapore's Health Sciences Authority has granted regulatory approval of Guardant360® CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling in patients with advanced solid cancers. The Guardant360 CDx test was also approved as a companion diagnostic to identify patients with advanced non-small cell lung cancer with epidermal growth factor receptor alterations who may benefit from treatment with TAG...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us